2026-08-07 国立がん研究センター,静岡県立静岡がんセンター,神奈川県立がんセンター,日本臨床腫瘍研究グループ
図1 内視鏡的粘膜下層剥離術（ESD）（出典：国立がん研究センターがん情報サービス）
＜関連情報＞
- https://www.ncc.go.jp/jp/information/pr_release/2026/0807/index.html
- https://www.gastrojournal.org/article/S0016-5085(26)07058-7/abstract?referrer=https%3A%2F%2Fwww.ncc.go.jp%2F
非ランダム化単群検証試験（JCOG1009/1010）における、潰瘍を伴わない臨床T1a未分化型早期胃癌（2cm以下）に対する内視鏡的粘膜下層剥離術後の10年間の追跡調査
10-Year Follow-Up After Endoscopic Submucosal Dissection for Clinical T1a Undifferentiated-Type Early Gastric Cancer ≤2 cm Without Ulceration in a Nonrandomized, Single-Arm Confirmatory Trial (JCOG1009/1010)
Seiichiro Abe ∙ Kohei Takizawa ∙ Hiroyuki Ono ∙ … ∙ Takaki Yoshikawa ∙ Tomonori Yano On behalf of the Japan Clinical Oncology Group (JCOG)
Gastroenterology Published: August 6, 2026
DOI:https://doi.org/10.1053/j.gastro.2026.06.028
Endoscopic submucosal dissection (ESD) is an organ-preserving approach used for early gastric cancer (EGC).1 JCOG1009/1010, a multicenter, single-arm, confirmatory trial of ESD for clinical T1a undifferentiated type (UD)-EGC without ulceration (UL) ≤2 cm reported a 5-year overall survival (OS) rate of 99.3% (95% CI, 97.1%–99.8%), meeting the predefined threshold of 89.7%.2 Thus, the Japanese guidelines recommend ESD as the standard of care for UD-EGC that meets the clinical indications.3,4 However, concern remains that the risk of late metastatic recurrence beyond 5 years of follow-up after ESD may exceed that after gastrectomy. This final analysis evaluated 10-year OS after ESD in patients with UD-EGC.
